Many patients on Ozempic for Type 2 diabetes or off-label weight loss eventually consider switching to Wegovy — the FDA-approved version of semaglutide for chronic weight management. The active ingredient is identical, but the FDA indication, approved doses, and insurance coverage differ.
This guide walks through exactly how to make the switch.
Step 1: Discuss with your prescriber
Switching between semaglutide products is a clinical decision that requires prescriber involvement. Reasons to switch include:
- You want FDA-approved access to higher doses (Wegovy goes to 2.4mg; Ozempic maxes at 2mg per FDA labeling)
- Your insurance covers Wegovy but not off-label Ozempic
- Your goal is weight loss, not diabetes management
- You are eligible for the Wegovy savings card or manufacturer cash-pay program
Step 2: Dose matching
Your prescriber will match doses to maintain continuity. The transition is straightforward because the same active ingredient is used:
- Ozempic 0.25 mg → Wegovy 0.25 mg
- Ozempic 0.5 mg → Wegovy 0.5 mg
- Ozempic 1.0 mg → Wegovy 1.0 mg
- Ozempic 2.0 mg → Wegovy 1.7 mg or 2.4 mg (discuss with prescriber)
Step 3: Insurance navigation
This is often the most complex part. Commercial insurance coverage varies dramatically between Ozempic (diabetes indication) and Wegovy (weight loss indication).
- If you have insurance: check whether Wegovy is on your formulary, what tier, and what prior authorization requires
- If your insurance covers Ozempic but not Wegovy: ask about formulary exceptions
- If you are paying cash: compare Ozempic retail (~$968/mo) versus Wegovy cash-pay options ($299-499/mo)